The Ubiquitin Proteasome System as a Therapeutic Area in Parkinson’s Disease
Progenra Inc, February 2023 Parkinson’s disease (PD) is the most common neurodegenerative movement disorder. There are no available therapeutics that slow or halt the progressive loss of dopamine-producing neurons, which underlies the primary clinical symptoms. Currently approved PD drugs can provide symptomatic relief by increasing brain dopamine content or activity; however, the alleviation is temporary, […]
